Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was to compare the efficacy and safety of documented treatment with colistin monotherapy versus colistin plus meropenem in critically ill patients with CRAB infections at Chiang Mai University Hospital (CMUH). We conducted a retrospective cohort study of critically ill patients with CRAB infections in an ICU from 2015 to 2017, who received colistin monotherapy versus colistin plus meropenem. After propensity score matching, an adjusted odds ratio (aOR) of a 30-day mortality rate in patients who received colistin plus meropenem was 0.43 compared to those who received colistin monotherapy (95% CI, 0.23–0.82, p = 0.01). aORs of clinical response and microbiological response were also higher in patients who received colistin plus meropenem (1.81, 95% CI 1.01–3.26, p = 0.048 and 2.08, 95% CI 1.11–3.91, p = 0.023, respectively). There was no significant difference in nephrotoxicity (aOR, 0.76, 95% CI, 0.43–1.36, p = 0.363) between colistin monotherapy and colistin plus meropenem. In conclusion, the addition of meropenem to colistin caused a reduction in 30-day mortality, higher clinical and microbiological responses, and did not increase nephrotoxicity compared to colistin monotherapy. Furthermore, 30-day mortality was significantly related with age, receiving vasopressor, having malignancy, and the APACHE II score.
Highlights
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are a serious problem and increasing worldwide, in the intensive care unit (ICU) [1,2]
This study evaluated the efficacy of colistin plus meropenem combination therapy compared with colistin monotherapy in the treatment of critically ill patients with CRAB infections
After adjusting for potential confounders in baseline characteristics, we found that the treatment of CRAB infections with colistin plus meropenem was associated with approximately 0.4 times the risk of 30-day mortality compared to treatment with colistin monotherapy
Summary
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are a serious problem and increasing worldwide, in the intensive care unit (ICU) [1,2]. The incidence of A. baumannii in ICU in Europe, Eastern Mediterranean and Africa was 56.5 cases per 1000 patients. A. baumannii infections in ICUs, the incidence was 41.7 cases per 1000 patients. In ICUs, A. baumannii and carbapenem-resistant A. baumannii strains accounted for 20.9% of all hospital-acquired A. baumannii infections [3]. The prevalence of CRAB in other studies was 70.5–91% in Singapore, more than 90% in Vietnam and 46.7–80% in Thailand [4]. The mortality rate of A. baumannii infection in hospital was 35.3%
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
